A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study (Phase I) to Evaluate the Tolerability and Pharmacokinetics of Belviq in Adult Korean Volunteers
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Adverse reactions
- Acronyms Belviq PK
- Sponsors Ildong Pharmaceutical
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jun 2013 New trial record